Background Tissue distribution after local delivery has been quantified over a period of 5 hours on 7-T MRI in a rabbit model using gadolinium-labeled diethylenetriamine pentaacetic acid (Gd-DTPA) as an antimicrobial surrogate; however, it is unknown how the Gd-DTPA load in a local depot will affect the duration of high-concentration Gd-DTPA in local tissues after surgical débridement. Questions/purposes We determined whether the Gd-DTPA load in bone cement affected its local tissue distribution over a period of 1 month after local delivery.
Introduction
Local delivery of antimicrobials from polymethylmethacrylate was pioneered by Buchholz et al. [4] in the early 1970s. It has since become a widely accepted technique employed in the management of osteomyelitis and periprosthetic joint infection [15, 16] . For treatment of established orthopaedic infections, local delivery is typically performed using high-dose antimicrobial-loaded bone cement (ALBC) beads, chips, or spacers, as part of a twostage treatment plan [16] .
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There is a wide variation in the complexity of postdébridement surgical wounds and local antimicrobial delivery, case by case and surgeon to surgeon. It is not surprising that clinical outcomes are variable [17] . Authors from the FDA recently concluded that there was no association between the eradication of infection and the use of local antimicrobial delivery [17] .
In an effort to determine the important parameters for effective local delivery, many authors have studied antimicrobial elution in vitro [8, 18, 19] . Elution studies evaluate the delivery vehicle's maximum capability to release antimicrobial, often inappropriately comparing eluant concentrations to the minimum inhibitory concentration (MIC) of target organisms. However, the critical information, not determined by elution studies, is in vivo antimicrobial concentration achieved from local delivery throughout surgical wounds after débridement. While a depot may be releasing antimicrobials, the flux of antimicrobial may not be enough to overcome clearance, consequently failing to achieve concentrations high enough to manage residual bacteria in biofilm. Adams et al. [1] attempted to address this question with a study of antimicrobial levels from ALBC beads in a canine tibia model. For delivery durations of 1 week to 1 month, antimicrobial concentrations reached levels above MIC in discrete tissue biopsies. However, tissue biopsies inherently do not provide continuous spatial and temporal distributions. Our laboratory has previously reported on gadolinium-labeled diethylenetriamine pentaacetic acid (Gd-DTPA) as an antimicrobial surrogate and the ability of 7-T MRI to quantify the distribution of Gd-DTPA over a period of 5 hours after local delivery throughout surgical wounds [13, 14] . Although Gd-DTPA is not intracellularly transported [14] and does not bind protein as some antimicrobials do at systemic concentrations, it does have similar molecular weight, solubility, and diffusivity and will be locally transported very similarly to many water-soluble antimicrobials [14] .
It remains unknown how antimicrobial load in ALBC affects duration of high antimicrobial concentration from local delivery in local tissues after surgical débridement for durations of more than 5 hours. We determined whether the initial load of Gd-DTPA (antimicrobial surrogate) in bone cement affected its local tissue distribution over a period of 1 month after local delivery.
Materials and Methods

Study Design
We studied the distribution of Gd-DTPA as an antimicrobial surrogate from Gd-DTPA-loaded bone cement (GLBC) as previously described [13, 14] . Standardized GLBC implants made with three Gd-DTPA loads were implanted in a rabbit wound model and imaged at 7, 14, and 33 days. Susceptibility artifacts caused by Gd in the implant required temporary exchange of the delivery implant with a Gd-free implant to acquire the images. Differences in volume of Gd-DTPA distribution based on Gd-DTPA load and time were analyzed with ANOVA.
Implant Preparation
GLBC was formulated with 1, 4, or 10 g Gd-DTPA (Sigma Aldrich, St Louis, MO, USA) mixed into 40 g Simplex P 1 Bone Cement polymer powder and 20 mL liquid monomer (Stryker Orthopaedics, Mahwah, NJ, USA). Mixing was performed manually with a spatula, without vacuum. Cement was mixed until dough phase and then formed into 1-cm cubes in a custom Teflon 1 mold. Control bone cement cubes that contained no Gd-DTPA were molded similarly. Cement was allowed to cure for 24 hours. Each cube weighed about 1.6 g. The 1-g Gd-DTPA per batch cubes had approximately 26 mg Gd-DTPA per implant, the 4-g Gd-DTPA per batch cubes had approximately 100 mg Gd-DTPA, and the 10-g Gd-DTPA per batch cubes had approximately 229 mg Gd-DTPA.
Surgical Procedure
All procedures were compliant with the NIH guidelines for the care and use of laboratory animals and approved by the Institutional Animal Care and Use Committee (IACUC) at St Joseph's Hospital (Phoenix, AZ, USA) (Protocol 434; initial approval May 31, 2012). Surgical anesthesia was induced with ketamine/xylazine and maintained with 2% isoflurane. Antimicrobial prophylaxis was given using intravenous gentamicin. Postoperative pain management was accomplished with slow-release buprenorphine.
Large surgical dead space relative to the size of the rabbit thigh was created, midthigh, through an anterolateral incision by resecting 1.0 cm 3 (1.0 ± 0.1 g) of quadriceps muscle adjacent to the femur. Superficially, a 5-mm thickness of muscle was preserved. A defect cross section of 1 cm was the largest defect that could be reproducibly created adjacent to bone with intact overlying muscle. A defect length of 1 cm was selected to allow 2 cm or more of intact muscle proximally and distally for penetration by locally delivered Gd-DTPA. Superficial muscle, fascia lata, and skin were closed in layers with 4-0 Prolene TM suture (Ethicon, Inc, Somerville, NJ, USA) after implantation of the local depot implant. Each animal underwent bilateral procedures with implants containing different Gd-DTPA loads. In total, 14 wounds were created and the dead space filled with GLBC implants: four with 10-g Gd-DTPA per batch loading, four with 4-g Gd-DTPA per batch loading, four with 1-g Gd-DTPA per batch loading, and two controls with no Gd-DTPA.
Imaging was performed on Days 7, 14, and 33. Artifacts from high concentrations of Gd within the GLBC implants (large black voids in the image) necessitated the removal of the GLBC implants before imaging. The wound space was maintained with a Gd-free implant during imaging. Fibrosis adjacent to the implants resulted in identifiable dead space providing guidance for implant placement (Fig. 1 ). The implant was gently removed from the implantation site through the same approach as used for the index procedure. A Gd-free implant was placed in the surgical dead space and the wound was closed with suture. The original GLBC implant was replaced after imaging, with closure of the wound in layers similar to the index procedure. There was minimal fluid surrounding the implant at each exchange. At 7 days, there were four replicates per dose. At 14 days, there were three replicates for the 10-and 1-g doses and two replicates for the 4-g dose. At 33 days, there was one replicate for the 10-and 1g doses and two replicates for the 4-g dose. This design was adopted due to concerns by the IACUC about animal discomfort and tolerance of the repeated surgical procedures to temporarily exchange the GLBC implant with a no-Gd implant for imaging. Euthanasia was accomplished after the final imaging with Beuthanasia 1 -D solution (1-2 mL/animal) (Merck, Whitehouse Station, NJ, USA) and thoracotomy as a secondary method.
In Vivo Imaging
In vivo images were taken with a Bruker BioSpin 1 7-T MRI unit (Bruker BioSpin Corp, Billerica, MA, USA).
Forty-two axial fat-suppressed T1-weighted rapid acquisition with relaxation enhancement (RARE) images were collected of the thighs from hip to knee. Each slice was 2 mm thick, with voxel sizes of 0.3 x 0.3 x 2 mm. The instrument was calibrated to company specifications to ensure spatial accuracy and evaluated daily via phantom imaging. A series of T1-weighted RARE images (TR: 1463, 2000, 3000, and 5000 milliseconds) were obtained. Previously published image processing techniques were used to produce concentration maps and three-dimensional projections of the volume of distribution of the locally delivered Gd-DTPA [14] . All voxels with Gd-DTPA concentration values of 14 lg/mL or more were used to construct concentration maps and volume projections.
Statistical Analysis
Differences in volume of distribution on Day 7 were determined with single-factor ANOVA. The effect of dosage on volume of distribution over the 14-lg/mL threshold over time was determined using repeated-measures ANOVA with dose and time as variables. Standard normal plots of residuals were constructed to ensure that the ANOVA model was well behaved [3] . Post hoc comparison was accomplished by t-testing among doses at 7, 14, or 33 days. We performed all statistical analyses using Minitab 15 (Minitab Inc, State College, PA, USA).
Results
The implants were surrounded by healthy minimally vascularized fibrous tissue consistent with the wound healing time and there was minimal fluid around the implants at each implant exchange (Fig. 1) . The volume of tissue with Gd-DTPA above the 14-lg/mL threshold on Day 7 was highest for the 10-g Gd-DTPA per batch implants (p = 0.002, ANOVA) and decreased by Day 33 down to levels similar to the volumes for the 1-and 4-g formulations at the earlier time points ( Table 1 ). The volume of distribution from the 10-g formulation was larger than the 4-g formulation (p = 0.0260, unpaired t-test) and the 1-g formulation (p = 0.0261, unpaired t-test). The higher volume of distribution for the 10-g Gd-DTPA formulation was sustained over the first 14 days, greater than the duration found with the 4-and 1-g formulations (p = 0.09, unpaired t-test). As in previous investigations, Gd-DTPA transport away from the depot was seen to penetrate into transected muscle (Fig. 2) [14] and along tissue planes but not across intact fascia or bone (Fig. 3) . 
Discussion
Local delivery is an accepted treatment modality for established orthopaedic infections [17] ; however, treatment failures continue with the likelihood that at least some of the failures are related to not achieving adequate antimicrobial levels from the local delivery throughout the postdébridement surgical wound [6, 9, 16] . We sought to provide additional data to characterize the distribution of locally delivered antimicrobials using quantitative MRI and Gd-DTPA as an imageable antimicrobial surrogate. We therefore determined whether the Gd-DTPA load in bone cement affected the Gd-DTPA distribution over a period of 1 month after local delivery.
There are some important limitations to this study. First, the in vivo study was performed in rabbits, not humans. Rabbits have much less tissue volume than humans. The volume of distribution is likely artificially constrained by the relatively small tissue volume surrounding the implant. Second, this study used Gd-DTPA, an antimicrobial surrogate that is visible on MRI (similar molecular size and solubility). The validity of the surrogate is supported by the general agreement of our results (Gd-DTPA delivery) with Values are mean ± 95% CI; * p = 0.026 versus 1 and 4 g; p = 0.094 versus 1 and 4 g; à single data point is an outlier inconsistent with release and transport kinetics; data not reported; Gd-DTPA = gadolinium-labeled diethylenetriamine pentaacetic acid. those of Adams et al. [1] . Unpublished release studies from ALBC performed by us document molar equivalent release of Gd-DTPA and vancomycin when loaded into cement in equimolar ratios. Gd-DTPA does not bind to protein, does not enter cells, and has no antimicrobial activity. While Gd-DTPA will not affect the cells that it comes near, the effects of protein binding and intracellular transport on the respective concentrations observed are likely to be minimal because the amount of antimicrobial that is lost to protein binding and intracellular uptake is small compared to the total amount of antimicrobial present [5] . Third, the imaging intervals were too long to detect the maximum volume of distribution for the 4-and 1-g formulations. We determined the imaging interval based on the data from Adams et al. [1] , with the expectation that levels would be elevated for 2 weeks or more. Our data are consistent with levels below threshold in tissues very near the depot before the 7-day imaging for both the low-and intermediate-dose formulations. Only the 10-g Gd-DTPA per batch formulation had sufficient release of Gd-DTPA to sustain levels above threshold at a distance from the depot for 7 days or more. Fourth, the delivery site in our model is completely within soft tissue. Soft tissue is expected to have higher clearance than sites within bone. Therefore, the duration of high levels may be shorter than what would be expected from spacers that are surrounded by bone [11, 24] . The difference in delivery sites, soft tissue versus bone, is not addressed by this study or the study by Adams et al. [1] . Fifth, our experimental models do not include the presence of active infection with the highly vascularized granulation tissue that can be present clinically, but the model is very similar to the postdébridement wound space that would be expected in clinical practice. Sixth, data collection past 2 weeks was limited by IACUC concern for repeat surgery and compassionate use of animals because of the necessity for replacing the implants at each serial imaging time.
We know that the amount of antimicrobial (or Gd-DTPA) released from cement is affected both by the amount of drug loaded [21, 22] and the porosity of the cement [23] . McLaren et al. [21] showed relatively similar elution from all of the commercially available ''low-dose'' formulations, although the current study only evaluated Simplex 1 . The Gd-DTPA distribution from local delivery observed in this study was maintained above the imaging threshold for less than a month. The MRI threshold used in our study and previously reported work is approximately 14 lg/mL Gd-DTPA [14] . Gd-DTPA has 2.8 times as many active molecules as gentamicin sulfate, based on molecular weight and the amount of sulfate in gentamicin sulfate. Organisms encountered clinically in orthopaedic infections have MICs for gentamicin of 0.5 to 2 lg/mL [12] , with the National Committee on Clinical Laboratory Standards determining gentamicin resistance at 4 lg/mL [7] ; 14 lg/mL Gd-DTPA is 78 times (14/0.5 x 2.8) the molar equivalent of gentamicin at the lower end of its susceptibility range. Levels above the imaging threshold are near the clinical target level of 100 to 1000 times levels needed to kill planktonic organisms [10] . Gd-DTPA levels are progressively higher closer to the depot. While we did not determine how high the levels reached at the depot surface, we did determine that tissues further from the depot are below clinically targeted levels. Tissue levels detectable on MRI are in the appropriate range to study the performance of clinically relevant antimicrobial depots. Elution studies suggest that delivery vehicles can release antimicrobials for several months. Our study documented concentrations near the depot that were near the target levels or greater for only a few weeks, even when a highdose formulation, 10 g Gd-DTPA per batch or greater, is used. The relatively short duration of high levels in tissue may be due to clearance Gd-DTPA occurring faster than it is being released after a few weeks [20] . Our data are consistent with the data of Adams et al. [1] , who showed that antimicrobial concentrations dropped below the break point sensitivity limit (* 1-8 lg/mL, different for each antimicrobial) after 9 to 14 days of release from bone cement with 6 to 9 g antimicrobial per 40-g batch. Our current study adds two pieces of knowledge to the literature that were not studied by Adams et al. [1] . The formulations used in that study were in the intermediate range (6-9 g per 40-g batch), greater than available commercially for prophylaxis but not in the high-dose range of 10 g per batch or greater [16] . Our study compared the performance of low-(1-g), intermediate-(4-g), and high-dose (10-g) formulations. Second, the high degree of spatial and temporal information available from MRI provides much more detailed knowledge of the location and duration of antimicrobial distribution than was available with the biopsy and bioassay methods described by Adams et al. [1] .
While the data generated from this in vivo MRI study are in good agreement with Adams et al. [1] , there are significant limitations with scale-up of the MRI method. Antimicrobial contained in ALBC dissolves and then diffuses out of the cement over time. It is now understood that fluid flow into ALBC or GLBC, and therefore antimicrobial diffusion out, is mediated by Washburn kinetics. Interstitial pressure forces fluid into the (small) pores in the ALBC. Fluid penetration is slowed by drag from the pore walls as the fluid penetrates more deeply into the cement. Because of this phenomenon, high-dose GLBC will always have a small volume of very high concentration Gd dissolved within it, leading to image artifact. Removal of the depot for imaging is not an option in the clinical setting so, if distribution after local delivery in clinical practice is to be imaged with MRI, the technique needs refinement. There are several options to control the artifact. Lower magnet strength (1.5 or 3 T) has less susceptibility to this artifact. Lower concentrations of contrast agents mixed with active antimicrobial or the development of new contrast agents that do not create an artifact at high concentrations is also possible. One potential example could be a chemical exchange saturation transfer agent that could generate signal in a concentration-dependent manner [2] .
This study established that, in a rabbit model, volumetric distribution after local delivery was dose dependent and that the duration over which high levels were maintained was less than expected, between 2 weeks and 1 month for high-dose (10-g per batch) formulations. Tissue levels detectable on MRI were in the appropriate range to study the performance of clinically relevant antimicrobial depots.
